Drug-related dyslipidemia after renal transplantation

American Journal of Health-System Pharmacy

Volumn 61, Issue 6, 2004, Pages 565-587

  Mathis, A Scott ^a,b   Davé, Nisha ^c   Knipp, Gregory T ^a   Friedman, Gary S ^d  

^a RUTGERS UNIVERSITY   (United States)

^b SAINT BARNABAS MEDICAL CENTER   (United States)

^c Pharmaceut Indust Fellowship Inst

^d Kidney Diseases and Cell Therapies   (United States)

Author keywords

Antilipemic agents; Cyclosporine; Dosage; Fluvastatin; Hyperlipidemia; Immunosuppressive agents; Interactions; Mechanism of action; National Kidney Foundation; Nutrition; Pharmacokinetics; Prednisone; Protocols; Sirolimus; Steroids, cortico ; Toxicity

Indexed keywords

ATORVASTATIN; AZATHIOPRINE; CALCINEURIN INHIBITOR; CERIVASTATIN; CLOFIBRATE; COLESTYRAMINE; CORTICOSTEROID; CYCLOSPORIN; ESAPENT; EVEROLIMUS; EZETIMIBE; FIBRIC ACID DERIVATIVE; FISH OIL; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHYLPREDNISOLONE; MEVINOLIN; MIZORIBINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NICOTINIC ACID; PRAVASTATIN; PREDNISONE; PROBUCOL; PROLIPID; RAPAMYCIN; SIMVASTATIN; TACROLIMUS; UNCLASSIFIED DRUG; HYPOCHOLESTEROLEMIC AGENT; IMMUNOSUPPRESSIVE AGENT;

AREA UNDER THE CURVE; CLINICAL TRIAL; DIET THERAPY; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DYSLIPIDEMIA; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MYOPATHY; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; DRUG INTERACTION; HYPERLIPIDEMIA; PRACTICE GUIDELINE;

ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; DRUG INTERACTIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; PRACTICE GUIDELINES;

EID: 3142523352     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/61.6.565     Document Type: Review

References (196)

1. Schnuelle P, Lorenz D, Trede M et al. Impact of renal cadaveric transplantation on survival in end-stage renal failure: evidence for reduced mortality risk compared with hemodialysis during long-term follow-up. J Am Soc Nephrol. 1998; 9:2135-41.
2. Wolfe RA, Ashby VB, Milford EL et al. Comparisons of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med. 1999; 341:1725-30.
3. Howard RJ, Patton PR, Reed AI et al. The changing causes of graft loss and death after kidney transplantation. Transplantation. 2002; 73:1923-8.
4. National Kidney Foundation. Survival, mortality, and causes of death. Am J Kidney Dis. 2003; 41(suppl 4):151-64.
5. Paul LC. Chronic allograft nephropathy: an update. Kidney Int. 1999; 56:783-93.
6. Kasiske BL. Cardiovascular disease after renal transplantation. Semin Nephrol. 2000; 20:176-87.
7. Kasiske BL. Risk factors for accelerated atherosclerosis in renal transplant recipients. Am J Med. 1988; 84:985-92.
8. Aker S, Ivens K, Guo Z et al. Cardiovascular complications after renal transplantation. Tranplant Proc. 1998; 30: 2039-42.
9. Aakus S, Dahl K, Wideroe TE. Cardiovascular morbidity and risk factors in renal transplant patients. Nephrol Dial Transplant. 1999; 14:648-54.
10. Kasiske BL, Chakkera HA, Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol. 2000; 11:1735-43.
11. Demirag A, Moray G, Ozdemir N et al. Comparison of serum lipids, lipoproteins, and fibrinogen in patients with kidney transplantation and hemodialysis. Transplant Proc. 1998; 30:2052-3.
12. Murgia MG, Jordan S, Kahan BD. The side effect profile of sirolimus: a phase I study of quiescent cyclosporine-prednisone-treated renal transplant patients. Kidney Int. 1996; 49:209-16.
13. Kahan BD, Kaplan B, Lorber MI et al. RAD in de novo renal transplantation: comparison of three doses on the incidence and severity of acute rejection. Transplantation. 2001; 71:1400-6.
14. Raine AE, Carter R, Mann JI et al. Adverse effect of cyclosporine on plasma cholesterol in renal transplant recipients. Nephrol Dial Transplant. 1988; 3:458-63.
15. Ichimaru N, Takahara S, Kokado Y et al. Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus. Atherosclerosis. 2001; 158:417-23.
16. Flechner SM, Goldfarb D, Modlin C et al. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation. 2002; 74:1070-6.
17. Blum CB. Effects of sirolimus on lipids in renal allograft recipients: an analysis using Framingham risk model. Am J Transplant. 2002; 2:551-9.
18. Venkiteswaran K, Sgoutas DS, Santanam N et al. Tacrolimus, cyclosporine and plasma lipoproteins in renal transplant recipients. Transpl Int. 2001; 14:405-10.
19. Vanrenterghem Y, Lebranchu Y, Hene R et al. Double-blind comparison of two corticosteroid regimens plus mycophenolate mofetil and cyclosporine for prevention of acute renal allograft rejection. Transplantation. 2000; 70:1352-9.
20. Johnson C, Ahsan N, Gonwa T et al. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate after cadaveric kidney transplantation. Transplantation. 2000; 69:834-41.
21. Jurewicz WA. Immunological and non-immunological risk factors with tacrolimus and Neoral in renal transplant recipients: an interim report. Transplant Proc. 1999; 31(suppl 7A):64S-6S.
22. Claesson K, Mayer AD, Squiffiet JP et al. Lipoprotein patterns in renal transplant patients: a comparison between FK 506 and cyclosporine A patients. Transplant Proc. 1998; 30:1292-4.
23. Satterthwaite R, Aswad S, Sunga V et al. Incidence of new-onset hypercholesterolemia in renal transplant patients with FK506 or cyclosporine. Transplantation. 1998; 65:446-9.
24. Galiatsou E, Morris ST, Jardine AG et al. Cardiac and vascular abnormalities in renal transplant patients: differential effects of cyclosporine and azathioprine. J Nephrol. 2000; 13:185-92.
25. Ligtenberg G, Hene RJ, Blankestijn PJ et al. Cardiovascular risk factors in renal transplant patients: cyclosporine A versus tacrolimus. J Am Soc Nephrol. 2001; 12:368-73.
26. Gamba A, Mamprin F, Fiocchi R et al. The risk of coronary artery disease after heart transplantation is increased in patients receiving low-dose cyclosporine, regardless of blood cyclosporine levels. Clin Cardiol. 1997; 20:767-72.
27. Aguilar-Salinas CA, Diaz-Polanco A, Quintana E et al. Genetic factors play an important role in the pathogenesis of hyperlipidemia post-transplant. Am J Kidney Dis. 2002; 40:169-77.
28. Massy ZA. Hyperlipidemia and cardiovascular disease after organ transplantation. Transplantation. 2001; 72(suppl): S13-5.
29. John GT, Dakshinamurthy DS, Jeyaseelan L et al. The effect of cyclosporine A on plasma lipids during the first year after transplantation. Natl Med J India. 1999; 12:14-7.
30. Kuster GM, Drexel H, Bleisch JA et al. Relation of cyclosporine blood levels to adverse effects on lipoproteins. Transplantation. 1994; 57:1479-83.
31. Matzkies FK, Keuthage W, Kobelt V et al. Cyclosporine does not influence serum cholesterol in kidney transplant recipients. Transplant Proc. 2002; 34:1795-6.
32. Margreiter R, European Tacrolimus vs Ciclosporin Microemulsion Renal Transplantation Study Group. Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study. Lancet. 2002; 359:741-6.
33. Hohage H, Arlt M, Bruckner D et al. Effects of cyclosporine A and FK 506 on lipid metabolism and fibrinogen in kidney transplant recipients. Clin Transplant. 1997; 11:225-30.
34. Raofi V, Holman DM, Coady N et al. A prospective randomized trial comparing the efficacy of tacrolimus versus cyclosporine in black recipients of primary cadaveric renal transplants. Am J Surg. 1999; 177:299-302.
35. Boots JM, van Duijnhoven EM, Christiaans MH et al. Single-center experience with tacrolimus versus cyclosporine-Neoral in renal transplant recipients. Transpl Int. 2001; 14:370-83.
36. Vela CG, Cristol JP, Descomps B et al. Prospective study of lipid disorders in FK506-versus cyclosporine-treated renal transplant recipients. Transplant Proc. 2000; 32:398.
37. Pirsch JD, Miller J, Deierhoi MH et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation. 1997; 63:977-83.
38. Jensik SC. Tacrolimus (FK506) in kidney transplantation: three-year survival results of the US multicenter, randomized comparative trial. Transplant Proc. 1998; 30:1216-8.
39. Miller LW. Cardiovascular toxicities of immunosuppressive agents. Am J Transplant. 2002; 2:807-18.
40. Elloso MM, Azrolan N, Sehgal SN et al. Protective effect of the immunosuppressant sirolimus against aortic atherosclerosis in apo e-deficient mice. Aro Am J Transplant. 2003; 3:562-9.
41. Brattstrom C, Wilczek HE, Tyden G et al. Hypertriglyceridemia in renal transplant recipients treated with sirolimus. Transplant Proc. 1998; 30:3950-1.
42. Kreis H, Cisterne JM, Land W et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation. 2000; 69:1252-60.
43. Morrisett JD, Abdel-Fattah G, Hoogeveen R et al. Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. J Lipid Res. 2002; 43:1170-80.
44. Kovarik JM, Kahan BD, Kaplan B et al. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine. Clin Pharmacol Ther. 2001; 69:48-56.
45. Vathsala A, Weinberg RB, Schoenberg L et al. Lipid abnormalities in cyclosporine-prednisone-treated renal transplant recipients. Transplantation. 1989; 48:37-43.
46. Quaschning T, Mainka T, Nauck M et al. Immunosuppression enhances atherogenicity of lipid profile after transplantation. Kidney Int Suppl. 1999; 71:S235-7.
47. Kingsbury KJ, Bondy G. Understanding the essentials of blood lipid metabolism. Prog Cardiovasc Nurs. 2003; 18:13-8.
48. Vaziri ND, Liang K, Azad H. Effect of cyclosporine on HMG-CoA reductase, cholesterol 7α-hydroxylase, LDL receptor, HDL receptor, VLDL receptor, and lipoprotein lipase expressions. J Pharmacol Exp Ther. 2000; 294:778-83.
49. Rayyes OA, Wallmark A, Floren CH. Additive inhibitory effect of hydrocortisone and cyclosporine on low-density lipoprotein receptor activity in cultured HepG2 cells. Hepatology. 1997; 26:967-71.
50. Apanay DC, Neylan JF, Ragab MS et al. Cyclosporine increases the oxidizability of low-density lipoproteins in renal transplant recipients. Transplantation. 1994; 58:663-9.
51. Ghanem H, van den Dorpel MA, Weimar W et al. Increased low density lipoprotein oxidation in stable kidney transplant recipients. Kidney Int. 1996; 49:488-93.
52. Morena M, Vela C, Garrigue V et al. Low-density lipoprotein composition and oxidation are not influenced by calcineurin inhibitors in renal transplant patients. Transplant Proc. 2000; 32:2785-6.
53. Varghese Z, Fernando RL, Turakhia G et al. Oxidizability of low-density lipoproteins from Neoral and tacrolimus-treated renal transplant patients. Transplant Proc. 1998; 30:2043-6.
54. Hoogeveen RC, Ballantyne CM, Pownall HJ et al. Effect of sirolimus on the metabolism of apoB100-containing lipoproteins in renal transplant patients. Transplantation. 2001; 72:1244-50.
55. Tur MD, Garrigue V, Vela C et al. Apolipoprotein CIII is upregulated by anticalcineurins and rapamycin: implications in transplantation-induced dyslipidemia. Transplant Proc. 2000; 32:2783-4.
56. Massy ZA, De Bandt JP, Morelon E et al. Hyperlipidaemia and post-heparin lipase activities in renal transplant recipients treated with sirolimus or cyclosporin A. Nephrol Dial Transplant. 2000; 15:928. Letter.
57. Ong CS, Pollack CA, Caterson RJ et al. Hyperlipidemia in renal transplant recipients: natural history and response to treatment. Medicine. 1994; 73:215-23.
58. Kasiske BL, Guijarro C, Massy ZA et al. Cardiovascular disease after renal transplantation. J Am Soc Nephrol. 1996; 7:158-65.
59. Aakhus S, Dahl K, Wideroe TE. Hyperlipidaemia in renal transplant patients. J Intern Med. 1996; 239:407-15.
60. Rodrigo E, Gonzalez-Lamuno D, Ruiz JC et al. Apolipoprotein C-III and E polymorphisms and cardiovascular syndrome, hyperlipidemia, and insulin resistance in renal transplantation. Am J Transplant. 2002; 2:343-8.
61. Massy ZA, Mamzer-Bruneel MF, Chevalier A et al. Carotid atherosclerosis in renal transplant recipients. Nephrol Dial Transplant. 1998; 13:1792-8.
62. Barbagallo CM, Pinto A, Gallo S et al. Carotid atherosclerosis in renal transplant recipients: relationships with cardiovascular risk factors and plasma proteins. Transplantation. 1999; 67:366-71.
63. Markell MS, Sumrani N, DiBenedetto A et al. Effect of hyperlipidemia on graft and patient survival in cyclosporine-treated renal transplant patients. Am J Kidney Dis. 1993; 22:233-9.
64. Wissing KM, Abramowicz D, Broeders N et al. Hypercholesterolemia is associated with increased kidney graft loss caused by chronic rejection in male patients with previous acute rejection. Transplantation. 2000; 70:464-72.
65. Roodnat JI, Mulder PG, Zietse R et al. Cholesterol as an independent predictor of outcome after renal transplantation. Transplantation. 2000; 69:1704-10.
66. Vincenti F, Jensik SC, Filo RS et al. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. Transplantation. 2002; 73:775-82.
67. Toki M, Kyo M, Takahara S et al. Clinicopathological evaluation in non-episode biopsies of renal transplant allograft. Transpl Int. 2000; 13(suppl 1): S73-7.
68. Guijarro C, Massy ZA, Kasiske BL. Clinical correlation between renal allograft failure and hyperlipidemia. Kidney Int Suppl. 1995; 52:S56-9.
69. Knight RJ, Kerman RH, Welsh M et al. Chronic rejection in primary renal allograft recipients under cyclosporine-prednisone immunosuppressive therapy. Transplantation. 1991; 51:355-9.
70. Dimeny E, Fellstrom B, Larsson E et al. Chronic vascular rejection and hyperlipoproteinemia in renal transplant patients. Clin Transplant. 1993; 7:482-90.
71. Dimeny E, Tufveson G, Lithell H et al. The influence of pretransplant lipoprotein abnormalities on the early results of renal transplantation. Eur J Clin Invest. 1993; 23:572-9.
72. Carvalho MF, Soares V. Hyperlipidemia as a risk factor of renal allograft function impairment. Clin Transplant. 2001; 15: 48-52.
73. Isoniemi H, Nurminen M, Tikkanen MJ et al. Risk factors predicting chronic rejection of renal allografts. Transplantation. 1994; 57:68-72.
74. Yee GC, Salomon DR. Cyclosporine. In: Evans WE, Schentag JJ, Jusko WJ, eds. Applied pharmacokinetics: principles of therapeutic drug monitoring. 3rd ed. Vancouver: Applied Therapeutics; 1992:28-1-28-40.
75. Okuda T, Oh-i T. Cyclosporine A pharmacokinetics in a patient with psoriasis and obesity, presenting with high levels of low-density [correction for destiny] lipoproteins. Eur J Clin Pharmacol. 2002; 58:299-300. [Erratum, Eur J Clin Pharmacol. 2002; 58:563.]
76. Okuda T, Oh-i T. Cyclosporine A pharmacokinetics in a patient with psoriasis and obesity, presenting with high levels of low-density [correction for destiny] lipoproteins. Eur J Clin Pharmacol. 2002; 58:299-300. [Erratum, Eur J Clin Pharmacol. 2002; 58:563.]
77. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993; 269:3015-23.
78. Expert Panel on the Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001; 285:2486-97.
79. National Kidney Foundation. Introduction, assessment of dyslipidemias, treating dyslipidemias, and research recommendations. Am J Kidney Dis. 2003; 41 (suppl 3):S11-91.
80. Mathis AS, Florez RM, Lombardi T et al. Opportunity for pharmacists: cholesterol management in renal transplant recipients. Paper presented at ASHP Midyear Clinical Meeting. New Orleans, LA; 2001 Dec 6.
81. Colak T, Karakayali H, Yagmurdur MC et al. Effect of conversion from cyclosporine to tacrolimus on lipid profiles in renal transplant recipients. Transplant Proc. 2002; 34:2081-2.
82. Friemann S, Feuring E, Padberg W et al. Improvement of nephrotoxicity, hypertension, and lipid metabolism after conversion of kidney transplant recipients from cyclosporine to tacrolimus. Transplant Proc. 1998; 30:1240-2.
83. Artz MA, Boots JM, Ligtenberg G et al. Randomized conversion from cyclosporine to tacrolimus in renal transplant patients: improved lipid profile and unchanged plasma homocysteine levels. Transplant Proc. 2002; 34:1793-4.
84. Busque S, Demers P, St-Louis G et al. Conversion from Neoral (cyclosporine) to tacrolimus of kidney transplant recipients for gingival hyperplasia or hypertrichosis. Transplant Proc. 1998; 30: 1247-8.
85. Thorp M, DeMattos A, Bennett W et al. The effect of conversion from cyclosporine to tacrolimus on gingival hyperplasia, hirsutism and cholesterol. Transplantation. 2000; 69:1218-24.
86. McCune TR, Thacker LR II, Peters TG et al. Effects of tacrolimus on hyperlipidemia after successful renal transplantation: a Southeastern Organ Procurement Foundation multicenter clinical study. Transplantation. 1998; 65:87-92.
87. Higgins RM, Hart P, Lam FT et al. Conversion from tacrolimus to cyclosporine in stable renal transplant patients. Transplantation. 1999; 69:1736-9.
88. Van den Dorpel MA, Ghanem H, Rischen-Vos J et al. Conversion from cyclosporine A to azathioprine treatment improves LDL oxidation in kidney transplant recipients. Kidney Int. 1997; 51:1608-12.
89. Hilbrands LB, Demacker PN, Hoitsma AJ et al. The effects of cyclosporine and prednisone on serum lipid and (apo)lipoprotein levels in renal transplant recipients. J Am Soc Nephrol. 1995; 5:2073-81.
90. Suwelack B, Gerhardt U, Kobelt V et al. Design and preliminary results of a randomized study on the conversion of treatment with calcineurin inhibitors to mycophenolate mofetil in chronic renal graft failure: effect, on serum cholesterol levels. Transplant Proc. 2002; 34:1803-5.
91. Johnson RW, Kreis H, Oberbauer R et al. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation. 2001; 72:777-86.
92. Rigotti P, European Tacrolimus/MMF Transplantation Study Group. Patients with high cholesterol levels benefit most from early withdrawal of corticosteroids. Transplant Proc. 2002; 34:1797-8.
93. Lemieux I, Houde I, Pascot A et al. Effects of prednisone withdrawal on the new metabolic triad in cyclosporine-treated kidney transplant patients. Kidney Int. 2002; 62:1839-47.
94. Hricik DE, Mayes JT, Schulak JA. Independent effects of cyclosporine and prednisone on posttransplant hypercholesterolemia. Am J Kidney Dis. 1991; 18: 353-8.
95. Hollander AA, Hene RJ, Hermans J et al. Late prednisone withdrawal in cyclosporine-treated kidney transplant patients: a randomized study. J Am Soc Nephrol. 1997; 8:294-301.
96. De Sevaux RG, Hilbrands LB, Tiggeler RG et al. A randomized, prospective study on the conversion from cyclosporine-prednisone to cyclosporine- azathioprine at 6 months after renal transplantation. Transpl Int. 1998; 11(suppl 1):S322-4.
97. Ahsan N, Hricik D, Matas A et al. Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil-a prospective randomized study. Transplantation. 1999; 68:1865-74.
98. Ratcliffe PJ, Dudley CR, Higgins RM et al. Randomised controlled trial of steroid withdrawal in renal transplant recipients receiving triple immunosuppression. Lancet. 1996; 348:643-8.
99. Matl I, Lacha J, Lodererova A et al. Withdrawal of steroids from triple-drug therapy in kidney transplant patients. Nephrol Dial Transplant. 2000; 15:1041-5.
100. Curtis JJ, Galla JH, Woodford SY et al. Effect of alternate-day prednisone on plasma lipids in renal transplant recipients. Kidney Int. 1982; 22:42-7.
101. Cattran DC, Steiner G, Wilson DR et al. Hyperlipidemia after renal transplantation: natural history and pathophysiology. Ann Intern Med. 1979; 91:554-9.
102. Gonwa TA, Hricik DE, Brinker K et al. Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination. Transplantation. 2002; 74:1560-7.
103. Abramowicz D, Manas D, Lao M et al. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen in stable kidney transplant recipients: a randomized, controlled study. Transplantation. 2002; 74:1725-34.
104. Lippuner K, Casez JP, Horber FF et al. Effects of deflazacort versus prednisone on bone mass, body composition, and lipid profile: a randomized, double blind study in kidney transplant patients. J Clin Endocrinol Metab. 1998; 83:3795-802.
105. Meier-Kriesche H, Ardorfer JA, Kaplan B. The impact of body mass index on renal transplant outcomes: a significant independent risk factor for graft failure and patient death. Transplantation. 2002; 73:70-4.
106. Shen SY, Lukens CW, Alongi SV et al. Patient profile and effect of dietary therapy on post-transplant hyperlipidemia. Kidney Int Suppl. 1983; 16:S147-52.
107. Barbagallo CM, Cefalu AB, Gallo S et al. Effects of Mediterranean diet on lipid levels and cardiovascular risk in renal transplant recipients. Nephron. 1999; 82:199-204.
108. Gokal R, Mann JI, Moore RA et al. Hyperlipidemia following renal transplantation. Q J Med. 1979; 48:507-17.
109. Disler PB, Goldberg RB, Kuhn L et al. The role of diet in the pathogenesis and control of hyperlipidemia after renal transplantation. Clin Nephrol. 1981; 16: 29-34.
110. Nelson J, Beauregard H, Gelinas M et al. Rapid improvement of hyperlipidemia in kidney transplant patients with a multifactorial hypolipidemic diet. Transplant Proc. 1988; 20:1264-70.
111. Divakar D, Bailey RR, Price M et al. Effect of diet on posttransplant hyperlipidaemia. N Z Med J. 1992; 105:79-80.
112. Moore RA, Callahan MF, Cody M et al. The effect of the American Heart Association step one diet on hyperlipidemia following renal transplantation. Transplantation. 1990; 49:60-2.
113. Lal SM, Gupta N, Georgiev O et al. Lipid-lowering effects of fluvastatin in renal transplant patients. A clinical observation. Int J Artif Organs. 1997; 20:18-21.
114. Hines L. Can low-fat/cholesterol nutrition counseling improve food intake habits and hyperlipidemia of renal transplant patients? J Renal Nutr. 2000; 10:30-5.
115. Tonstad S, Holdaas H, Gorbitz C et al. Is dietary intervention effective in post-transplant hyperlipidaemia? Nephrol Dial Transplant. 1995; 10:82-5.
116. Lal SM, Trivedi HS, Van Stone JC et al. Effects of dietary therapy on post renal transplant hyperlipidemia. A prospective study. Int J Artif Organs. 1994; 17:461-5.
117. Hussein O, Rosenblat M, Refael G et al. Dietary selenium increases cellular glutathione peroxidase activity and reduces the enhanced susceptibility to lipid peroxidation of plasma and low-density lipoprotein in kidney transplant recipients. Transplantation. 1997; 63:679-85.
118. Gonyea JE, Anderson CF. Weight changes and serum lipoproteins in recipients of renal allografts. Mayo Clin Proc. 1992; 67:653-7.
119. Foldes K, Maklary E, Vargha P et al. Effect of diet and fluvastatin treatment on the serum lipid profile of kidney transplant, diabetic recipients: a 1-year follow-up. Transpl Int. 1998; 11(suppl 1): S65-8.
120. Akiyama T, Ishii T, Imanishi M et al. Efficacy and safety of treatment with low-dose fluvastatin in hypercholesterolemic renal transplant recipients. Transplant Proc. 2001; 33:2115-8.
121. Malyszko J, Malyszko JS, Brzosko S et al. Effects of fluvastatin on homocysteine and serum lipids in kidney allograft recipients. Ann Transplant. 2002; 7:52-4.
122. Hausberg M, Kosch M, Stam F et al. Effect of fluvastatin on endothelium-dependent brachial artery vasodilation in patients after renal transplantation. Kidney Int. 2001; 59:1473-9.
123. Melchor JL, Gracida C. Treatment of hypercholesterolemia with fluvastatin in kidney transplant patients. Transplant Proc. 1998; 30:2054.
124. Holdaas H, Jardine AG, Wheeler DC et al. Effect of fluvastatin on acute renal allograft rejection: a randomized multicenter trial. Kidney Int. 2001; 60:1990-7.
125. Kosch M, Barenbrock M, Suwelack B et al. Effect of a 3-year therapy with the 3-hydroxy-3-methylglutaryl coenzyme A reductase-inhibitor fluvastatin on endothelial function and distensibility of large arteries in hypercholesterolemic renal transplant recipient. Am J Kidney Dis. 2003; 41:1088-96.
126. Asberg A, Hartmann A, Fjeldsa E et al. Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients. Am J Transplant. 2001; 1:382-6.
127. Romero R, Calvino J, Rodriguez J et al. Short-term effect of atorvastatin in hypercholesterolaemic renal-transplant patients unresponsive to other statins. Nephrol Dial Transplant. 2000; 15:1446-9.
128. Renders L, Mayer-Kadner I, Koch C et al. Efficacy and drug interactions of the new HMG-CoA reductase inhibitors cerivastatin and atorvastatin in CsA-treated renal transplant recipients. Nephrol Dial Transplant. 2001; 16:141-6.
129. Kasiske BL, Tortorice KL, Heim-Duthoy KL et al. Lovastatin treatment of hypercholesterolemia in renal transplant recipients. Transplantation. 1990; 49:95-100.
130. Kandus A, Kovac D, Cerne D et al. Therapy of hyperlipidemia with lovastatin in kidney transplant patients on cyclosporine A immunosuppression: three-year experience. Transplant Proc. 1998; 30: 1307-9.
131. Kliem V, Wanner C, Eisenhauer T et al. Comparison of pravastatin and lovastatin in renal transplant patients receiving cyclosporine. Transplant Proc. 1996; 28: 3126-8.
132. Yoshimura N, Oka T, Okamoto M et al. The effects of pravastatin on hyperlipidemia in renal transplant recipients. Transplantation. 1992; 53:94-9.
133. Vaessen LM, van Miert PP, van Gelder T et al. Reassuring effect of pravastatin on natural killer cell activity in stable renal transplant patients. Transplantation. 2001; 71:1175-9.
134. Castelao AM, Grinyo JM, Castineiras MJ et al. Effect of pravastatin in the treatment of hypercholesterolemia after renal transplantation under cyclosporine and prednisone. Transplant Proc. 1995; 27: 2217-20.
135. Katznelson S, Wilkinson AH, Kobashigawa JA et al. The effect of pravastatin on acute rejection after kidney transplantation-a pilot study. Transplantation. 1996; 61:1469-74.
136. Capone D, Stanziale P, Gentile A et al. Effects of simvastatin and pravastatin on hyperlipidemia and cyclosporin blood levels in renal transplant recipients. Am J Nephrol. 1999; 19:411-5.
137. Martinez Hernandez BE, Persaud JW, Varghese Z et al. Low-dose simvastatin is safe in hyperlipidaemic renal transplant patients. Nephrol Dial Transplant. 1993; 8:637-41.
138. Arnadottir M, Eriksson LO, Germershausen JI et al. Low-dose simvastatin is a well-tolerated and efficacious cholesterol-lowering agent in ciclosporin-treated kidney transplant recipients: double-blind, randomized, placebo-controlled study in 40 patients. Nephron. 1994; 68:57-62.
139. Rigatto C, Rush D, Perry Y et al. Cholesterol reduction in cyclosporine-treated renal transplant patients: effect on platelet-derived growth factor levels and platelet activation. Transplant Proc. 1997; 29:2591-2.
140. Santos AF, Keitel E, Bittar AE et al. Safety and efficacy of simvastatin for hyperlipidemia in renal transplant recipients: a double-blind, randomized, placebo-controlled study. Transplant Proc. 2001; 33:1194-5.
141. Chan TM, Cheng IK, Tam SC. Hyperlipidemia after renal transplantation: treatment with gemfibrozil. Nephron. 1994; 67:317-21.
142. Vergoulas G, Miserlis G, Solonaki F et al. Combined treatment of hypercholesterolemia in renal transplant allograft recipients with fluvastatin and gemfibrozil. Transpl Int. 2000; 13(suppl 1): S64-7.
143. Lal SM, Hewett JE, Petroski GF et al. Effects of nicotinic acid and lovastatin in renal transplant patients: a prospective, randomized, open-labeled crossover trial. Am J Kidney Dis. 1995; 25:616-22.
144. Castro R, Queiros J, Fonseca I et al. Therapy of post-renal transplantation hyperlipidaemia: comparative study with simvastatin and fish oil. Nephrol Dial Transplant. 1997; 12:2140-3.
145. Grekas D, Kassimatis E, Makedou A et al. Combined treatment with low-dose pravastatin and fish oil in post-renal transplantation dislipidemia. Nephron. 2001; 88:329-33.
146. Bennett WM, Carpenter CB, Shapiro ME et al. Delayed omega-3 fatty acid supplements in renal transplantation. A double-blind, placebo-controlled study. Transplantation. 1995; 59:352-6.
147. Urakaze M, Hamazaki T, Yano S et al. Effect of fish oil concentrate on risk factors of cardiovascular complications in renal transplantation. Transplant Proc. 1989; 21:2134-6.
148. Bushnach G, Stragliotto E, Minetti E et al. Effect of n-3 polyunsaturated fatty acids on cyclosporine pharmacokinetics in kidney graft recipients: a randomized placebo-controlled study. J Nephrol. 1998; 11:87-93.
149. Santos J, Queiros J, Silva F et al. Effects of fish oil in cyclosporine-treated renal transplant recipients. Transplant Proc. 2000; 32:2605-8.
150. Cosio FG, Pesavento TE, Pelletier RP et al. Patient survival after renal transplantation III: the effects of statins. Am J Kidney Dis. 2002; 40:638-43.
151. Kobashigawa JA, Katznelson S, Laks H et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med. 1995; 333:621-7.
152. Wenke K, Meiser B, Thiery J et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation. A four-year randomized trial. Circulation. 1997; 96:1398-402.
153. Keogh A, Macdonald P, Kaan A et al. Efficacy and safety of pravastatin vs simvastatin after cardiac transplantation. J Heart Lung Transplant. 2000; 19:529-37.
154. Kasiske BL, Heim-Duthoy KL, Singer GG et al. The effects of lipid-lowering agents on acute renal allograft rejection. Transplantation. 2001; 72:223-7.
155. Sahu KM, Sharma RK, Gupta A et al. Effect of lovastatin, an HMG CoA reductase inhibitor, on acute renal allograft rejection. Clin Transplant. 2001; 15:173-5.
156. Kwak B, Mulhaupt F, Myit S et al. Statins as a newly recognized immunomodulator. Nat Med. 2000; 12:1399-402.
157. Palinski W, Tsimikas S. Immunomodulatory effects of statins: mechanisms and potential impact on arteriosclerosis. J Am Soc Nephrol. 2002; 13:1673-81.
158. Holdaas H, Fellstrom B, Jardine AG et al. Effects of fluvastatin on cardiac events in renal transplant recipients: a multicentre, randomized, placebo-controlled trial. Lancet. 2003; 361:2024-31.
159. Arnadottir M, Eriksson LO, Thysell H et al. Plasma concentration profiles of simvastatin 3-hydroxy-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin. Nephron. 1993; 65:410-3.
160. Xu F, Wu ZH, Zhang ZY et al. Delay of metabolism rate of ciclosporin by simvastatin in 7 Chinese healthy men. Acta Pharmacologica Sinica. 1998; 19:443-4.
161. Park JW, Siekmeier R, Merz M et al. Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. Int J Clin Pharmacol Ther. 2002; 40:439-50.
162. Park JW, Siekmeier R, Lattke P et al. Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A. J Cardiovasc Pharmacol Ther. 2001; 6:351-61.
163. Olbricht C, Wanner C, Eisenhauer T et al. Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. Clin Pharmacol Ther. 1997; 62: 311-21.
164. Schrama TC, Hene RJ, de Jonge N et al. Efficacy and muscle safety of fluvastatin in cyclosporine-treated cardiac and renal transplant recipients: an exercise provocation test. Transplantation. 1998; 66:1175-81.
165. Goldberg R, Roth D. Evaluation of fluvastatin in the treatment of hypercholesterolemia in renal transplant recipients taking cyclosporine. Transplantation. 1996; 62:1559-64.
166. Muck W, Mal I, Fritsche L et al. Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients. Clin Pharmacol Ther. 1999; 65:251-61.
167. Regazzi MB, Iacona I, Campana C et al. Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients. Transplant Proc. 1993; 25:2732-4.
168. Li PK, Mak TW, Wang AY et al. The interaction of fluvastatin and cyclosporin A in renal transplant patients. Int J Clin Pharmacol Ther. 1995; 33:246-8.
169. Gullestad L, Nordal KP, Berg KJ et al. Interaction between lovastatin and cyclosporin A after heart and kidney transplantation. Transplant Proc. 1999; 31: 2163-5.
170. Bogman K, Peyer AK, Torok M et al. HMG-CoA reductase inhibitors and P-glycoprotein modulation. Br J Pharmacol. 2001; 132:1183-92.
171. Paoletti R, Corsini A, Bellosta S. Pharmacological interactions of statins. Atheroscler Suppl. 2002; 3:35-40.
172. Asberg A. Interactions between cyclosporin and lipid-lowering drugs. Implications for organ transplant recipients. Drugs. 2003; 63:367-78.
173. Muck W, Neal DA, Boix O et al. Tacrolimus/cerivastatin interaction study in liver transplant patients. Br J Clin Pharmacol. 2001; 52:213-5.
174. Christians U, Jacobsen W, Benet LZ et al. Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet. 2002; 41:813-51.
175. Chen ZS, Kawabe T, Ono M et al. Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multispecific organic anion transporter. Mol Pharmacol. 1999; 56: 1219-28.
176. Yamazaki M, Akiyama S, Ni'inuma K et al. Biliary excretion of pravastatin in rats: contribution of the excretion pathway mediated by canalicular multispecific organic anion transporter. Drug Metab Dispos. 1997; 25:1123-9.
177. Lindahl A, Frid S, Ungell AL et al. No evidence for the involvement of the multidrug resistance-associated protein and/or the monocarboxylic acid transporter in the intestinal transport of fluvastatin in the rat. AAPS PharmSci. 2000; 2:e26.
178. White CM. A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin. J Clin Pharmacol. 2002; 42: 963-70.
179. Hibi S, Misawa A, Tamai M et al. Severe rhabdomyolysis associated with tacrolimus. Lancet. 1995; 346:702. Letter.
180. Ballantyne CM, Corsini A, Davidson MH et al. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med. 2003; 163:553-64.
181. Gruer PJ, Vega JM, Mercuri MF et al. Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin. Am J Cardiol. 1999; 84:811-5.
182. Maltz HC, Balog DL, Cheigh JS. Rhabdomyolysis associated with concomitant use of atorvastatin and cyclosporine. Ann Pharmacother. 1999; 33:1176-9.
183. Jones P, Kafonek S, Laurora I et al. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia. Am J Cardiol. 1998; 81:582-7.
184. Martinez-Castelao A, Grinyo JM, Gil-Vernet S et al. Lipid-lowering long-term effects of six different statins in hypercholesterolemic renal transplant patients under cyclosporine immunosuppression. Transplant Proc. 2002; 34: 398-400.
185. Bagdade JD, Shantharam VV, Sollek M et al. Effects of clofibrate on plasma lipids and high-density lipoprotein levels in renal allograft recipients. Clin Nephrol. 1979; 12:83-6.
186. Backman JT, Kyrklund C, Kivisto KT et al. Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther. 2000; 68: 122-9.
187. Kyrklund C, Backman JT, Kivisto KT et al. Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin Pharmacol Ther. 2001; 69:340-5.
188. Seral C, Michot JM, Chanteux H et al. Influence of P-glycoprotein inhibitors on accumulation of macrolides in J774 murine macrophages. Antimicrob Agents Chemother. 2003; 47:1047-51.
189. Broeders N, Knoop C, Antoine M et al. Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent? Nephrol Dial Transplant. 2000; 15:1993-9.
190. Lipscombe J, Lewis GF, Cattran D et al. Deterioration in renal function associated with fibrate therapy. Clin Nephrol. 2001; 55:39-44.
191. Jensen RA, Lal SM, Diaz-Arias A et al. Does cholestyramine interfere with cyclosporine absorption? A prospective study in renal transplant patients. ASAIO J. 1995; 41:M704-6.
192. Lal SM, Katyal A. Effects of nicotinic acid and lovastatin in combination with cholestyramine in renal transplant patients. Mo Med. 2002; 99:580-4.
193. Gallego C, Sanchez P, Planells C et al. Interaction between probucol and cyclosporine in renal transplant patients. Ann Pharmacother. 1994; 28: 940-3.
194. Maachi K, Berthoux P, Burgard G et al. Results of a 1-year randomized controlled trial with omega-3 fatty acid fish oil in renal transplantation under triple immunosuppressive therapy. Transplant Proc. 1995; 27:846-9.
195. Zetia package insert. Kenilworth, NJ: Merck/Schering-Plough Pharmaceuticals; 2002 Oct.
196. Ezzet F, Wexler D, Statkevich P et al. The plasma concentration and LDL-C relationship in patients receiving ezetimibe. J Clin Pharmacol. 2001; 41:943-9.